廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,010.66
    +17.52 (+0.59%)
     
  • 滬深300

    3,520.96
    +18.18 (+0.52%)
     
  • 美元

    7.8258
    +0.0028 (+0.04%)
     
  • 人民幣

    0.9229
    -0.0003 (-0.03%)
     
  • 道指

    39,776.24
    +16.16 (+0.04%)
     
  • 標普 500

    5,253.02
    +4.53 (+0.09%)
     
  • 納指

    16,384.90
    -14.62 (-0.09%)
     
  • 日圓

    0.0514
    -0.0000 (-0.04%)
     
  • 歐元

    8.4490
    -0.0202 (-0.24%)
     
  • 英鎊

    9.8780
    -0.0070 (-0.07%)
     
  • 紐約期油

    82.92
    +1.57 (+1.93%)
     
  • 金價

    2,239.80
    +27.10 (+1.22%)
     
  • Bitcoin

    70,673.68
    +1,562.78 (+2.26%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Edwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023

  • Edwards Lifesciences Corp (NYSE: EW) reported Q4 adjusted EPS of $0.64, up 25% Y/Y and higher than the consensus of $0.61.

  • The company reported Q4 revenues of $1.35 billion, up 1% and 7% on constant currency, beating the consensus of $1.33 billion.

  • While TAVR sales remained flat year over year, Edwards reported 1% growth for its structural heart business. It attributed that bump to its Resilia technologies launch and Mitris surgical mitral valve.

  • Outlook: Edwards Lifesciences reaffirmed its FY23 sales guidance in December 2022 to grow between 9%-12% to $5.6-$6 billion.

  • The company continues to expect the full year 2023 adjusted EPS of $2.45-$2.60.

  • For Q1 FY23, Edwards projects sales of $1.37-$1.45 billion and adjusted EPS of $0.58-$0.64.

  • "We expect meaningful growth and progress in 2023 with a gradual improvement in healthcare staffing and contributions from all major regions," Michael Mussallem, chairman & CEO, said.

  • Analyst Take: William Blair writes that easing headwinds in 2H of 2023 and a steady stream of commercial catalysts can allow for more robust growth rates and help drive share momentum. The analyst rates the stock as Outperforming.

  • Price Action: EW shares closed higher by 0.84% at $76.70 on Tuesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Edwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023 originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.